A synopsis of modern - day colorectal cancer: Where we stand

Ranasinghe, Ranmali; Mathai, Michael L.; Zulli, Anthony

doi:10.1016/j.bbcan.2022.188699

Cited by 20 publications

(8 citation statements)

References 248 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Te priority of chemotherapy in stage III is considered to be a possible reason for the better prognosis of stage III compared with T4N0 colon cancer patients [18,19]. Stage III patients are often recommended to have a higher rate of adjuvant chemotherapy, and postoperative adjuvant systemic therapy can signifcantly improve the prognosis [20,21]. With the emergence of various new drugs, as well as the wide application of immunotherapy and targeted therapy [22][23][24][25], the prognosis of stage III patients is becoming increasingly ideal.…”

Section: Discussionmentioning

confidence: 99%

Survival Contradiction in Stage II, IIIA, And IIIB Colon Cancer: A Surveillance, Epidemiology, and End Result-Based Analysis

Hua

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

There exists an inconsistency between stage and survival in the current American Joint Committee on Cancer (AJCC) staging system for colon cancer. In this study, we compared the clinicopathological characteristics and prognosis of colon cancer patients with stage II, IIIA, and IIIB disease based on the surveillance, epidemiology, and end results (SEER) database. Kaplan-Meier analysis was used to generate overall survival (OS) and cancer-specific survival (CSS) curves. The Cox regression was employed to identify risk factors. The competing risk model was completed by the cumulative incidence function and Gray’s test. In the final population of 31,361 colon cancer patients, Kaplan-Meier curve analysis showed that stage IIIA had the highest OS and CSS, followed by stage IIA and IIIB, and IIB and IIC showed the worst OS and CSS. In the Cox model, the stage was proven to be an independent prognostic factor. In the competing risk model, stage IIIA colon cancer patients had the lowest 5-year cancer-specific death rate in stages II, IIIA, and IIIB. In conclusion, the prognosis of colon cancer patients in stage IIA was worse than that of patients in stage IIIA, while the survival rate of stage IIB and IIC was lower than that of stage IIIB.

show abstract

Section: Discussionmentioning

confidence: 99%

Survival Contradiction in Stage II, IIIA, And IIIB Colon Cancer: A Surveillance, Epidemiology, and End Result-Based Analysis

Hua

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

show abstract

“…The ASIRs in most European countries exceeded 40 per 100,000—higher than the world average rate [ 44 ]. Norway ranks first for CRC in females while Hungary ranks first for CRC cases reported in males [ 45 ]. In Italy, CCR accounts for 12.7% of all cancers with 48.576 new cases diagnosed in 2020 (25,588 males and 22,988 females).…”

Section: Incidencementioning

confidence: 99%

“…The incidence of CCR in the United States accounts for 25.6 per 100,000 persons. Colon and rectal cancers incidences are low in Africa and Southern Asia [ 39 , 45 ].…”

Section: Incidencementioning

confidence: 99%

Colorectal Cancer: Current Updates and Future Perspectives

Marcellinaro,

Spoletini,

Grieco

et al. 2023

JCM

View full text Add to dashboard Cite

Colorectal cancer is a frequent neoplasm in western countries, mainly due to dietary and behavioral factors. Its incidence is growing in developing countries for the westernization of foods and lifestyles. An increased incidence rate is observed in patients under 45 years of age. In recent years, the mortality for CRC is decreased, but this trend is slowing. The mortality rate is reducing in those countries where prevention and treatments have been implemented. The survival is increased to over 65%. This trend reflects earlier detection of CRC through routine clinical examinations and screening, more accurate staging through advances in imaging, improvements in surgical techniques, and advances in chemotherapy and radiation. The most important predictor of survival is the stage at diagnosis. The screening programs are able to reduce incidence and mortality rates of CRC. The aim of this paper is to provide a comprehensive overview of incidence, mortality, and survival rate for CRC.

show abstract

“…Colorectal cancer (CRC) is the third leading malignancy and one of the major causes of cancer-related mortality in developed as well as developing countries [ 1 , 2 ]. Around the globe, nearly 1.4 million cases and about 694,000 deaths have been reported every year [ 3 , 4 ]. The early diagnosis of gene mutations may help to prevent disease progression [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

Synthesis and Cytotoxic Activity of 1,2,4-Triazolo-Linked Bis-Indolyl Conjugates as Dual Inhibitors of Tankyrase and PI3K

et al. 2022

View full text Add to dashboard Cite

A series of new 1,2,4-triazolo-linked bis-indolyl conjugates (15a–r) were prepared by multistep synthesis and evaluated for their cytotoxic activity against various human cancer cell lines. It was observed that they were more susceptible to colon and breast cancer cells. Conjugates 15o (IC50 = 2.04 μM) and 15r (IC50 = 0.85 μM) illustrated promising cytotoxicity compared to 5-fluorouracil (5-FU, IC50 = 5.31 μM) against the HT-29 cell line. Interestingly, 15o and 15r induced cell cycle arrest at the G0/G1 phase and disrupted the mitochondrial membrane potential. Moreover, these conjugates led to apoptosis in HT-29 at 2 μM and 1 μM, respectively, and also enhanced the total ROS production as well as the mitochondrial-generated ROS. Immunofluorescence and Western blot assays revealed that these conjugates reduced the expression levels of the PI3K-P85, β-catenin, TAB-182, β-actin, AXIN-2, and NF-κB markers that are involved in the β-catenin pathway of colorectal cancer. The results of the in silico docking studies of 15r and 15o further support their dual inhibitory behaviour against PI3K and tankyrase. Interestingly, the conjugates have adequate ADME-toxicity parameters based on the calculated results of the molecular dynamic simulations, as we found that these inhibitors (15r) influenced the conformational flexibility of the 4OA7 and 3L54 proteins.

show abstract

A synopsis of modern - day colorectal cancer: Where we stand

Cited by 20 publications

References 248 publications

Survival Contradiction in Stage II, IIIA, And IIIB Colon Cancer: A Surveillance, Epidemiology, and End Result-Based Analysis

Survival Contradiction in Stage II, IIIA, And IIIB Colon Cancer: A Surveillance, Epidemiology, and End Result-Based Analysis

Colorectal Cancer: Current Updates and Future Perspectives

Synthesis and Cytotoxic Activity of 1,2,4-Triazolo-Linked Bis-Indolyl Conjugates as Dual Inhibitors of Tankyrase and PI3K

Contact Info

Product

Resources

About